Phio Pharmaceuticals Corp. - 8-K Filing
Phio Pharmaceuticals reported Q1 2026 financial results with a net loss of $4.0 million, up from $1.8 million in Q1 2025, driven by a 215% increase in R&D expenses to $2.8 million due to PH-762 clinical and CMC activities. The company completed dose escalation for its lead candidate PH-762 in a Phase 1b trial for skin cancer and plans to submit an FDA proposal for next steps in Q2 2026. Cash and equivalents were $17 million as of March 31, 2026, down from $21 million at year-end 2025. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $PHIO